CJC-1295 research guide for Wright. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers searching for CJC-1295 in Wright immediately realize that local retail options are all but absent from local stores. This matters because CJC-1295 quality varies dramatically across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor controls every quality variable. What reliably differentiates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety screening. This guide gives Wright researchers the methodology to evaluate CJC-1295 vendors systematically and source high-purity CJC-1295 with confidence.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Wright researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
Before looking at individual vendors, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone provides no identity confirmation. For Wright researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before placing larger orders is standard practice in the community. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and store the rest at −20°C.
Order CJC-1295 — ships to Wright
COA-verified · International tracking · Research grade
All use of CJC-1295 in Wright or anywhere must be research use only — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger severe inflammatory responses at very low concentrations, and no cost saving makes omitting this acceptable. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is unapproved for human therapeutic application and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
